Skip to main content
Fig. 3 | BMC Medical Imaging

Fig. 3

From: Monitoring the efficacy of tumor necrosis factor alpha antagonists in the treatment of Ankylosing spondylarthritis: a pilot study based on MR relaxometry technique

Fig. 3

A male, 24 years old, HLA-B27: ± , ASDAS-CRP:3.8, belongs to the very high disease activity group. Depending on the different treatment cycles, these are pre-treatment (A,a), 3 weeks (B,b), 6 weeks (C,c) and 12 weeks (D,d) after treatment, respectively. A–D. Fat suppression PDWI sequences show the decreasing of sacroiliac bone marrow signal, gradually. the ASDAS-CRP score decreased with the increase of the treatment cycle (2.6, 1.6, 1.0, 0.6). a–d. T1-mapping pseudo-color diagrams also demonstrate the decreasing of the regions of interest T1-mapping value, gradually. (956.43, 780.73, 604.73, 349.27 ms).

Back to article page

BMC Medical Imaging

ISSN: 1471-2342

Contact us